HEALTHQUARTZ
Novo Nordisk stock sinks after anti-inflammatory heart drug fails late-stage trial
Novo Nordisk stock declined following the failure of its experimental anti-inflammatory drug ziltivekimab in a late-stage trial. The drug did not reduce major adverse cardiovascular events compared to a placebo in a study involving over 6,300 patients.
Mentioned
Related Signal
Adjacent reporting
- Novo Nordisk shares dive after heart medicine fails trial
- STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
- AstraZeneca stock plunges after late-stage heart drug trial misses its target
- AstraZeneca stock dives 9% after heart drug trial misses target
- Major drugmaker loses $27 billion in market value after failed trial